Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Karyopharm TherapeuticsKPTI +3.09%49 Days Inventory is 319.29 as of Jun. 2026, which is 19% above its 10-year median of 268.36. GuruFocus rates KPTI with a GF Score™ of 49/100 and a GF Value™ of $4.92 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 636 Biotechnology companies, Karyopharm Therapeutics ranks worse than 62.74% on this metric.
The historical rank and industry rank for Karyopharm Therapeutics's Days Inventory or its related term are showing as below:
KPTI'
s Days Inventory Range Over the Past 10 Years
Min: 52.47 Med: 268.36 Max: 362.1
Current: 249.38
During the past 13 years, Karyopharm Therapeutics's highest Days Inventory was 362.10. The lowest was 52.47. And the median was 268.36.
KPTI's Days Inventory is ranked worse than 62.74% of 636
companies
in the Biotechnology industry
Industry Median: 180.895
vs KPTI: 249.38
Karyopharm Therapeutics's Days Inventory
declined
from Jun. 2025 (423.74) to Jun. 2026 (319.29).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Karyopharm Therapeutics's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.29.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Karyopharm Therapeutics's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.11.
Karyopharm Therapeutics (NAS:KPTI) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Karyopharm Therapeutics's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Karyopharm Therapeutics's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Karyopharm Therapeutics Days Inventory Related Terms
Karyopharm Therapeutics Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KPTI vs TNYA, HUMA, CRBP: Days Inventory Comparison
For the Biotechnology subindustry, Karyopharm Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Karyopharm Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics (KPTI) has a Days Inventory of 319.29 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Karyopharm Therapeutics and its competitors. This is 19% above median its historical median of 268.36. Over the past decade, Karyopharm Therapeutics' Days Inventory has ranged from 52.47 to 362.10. According to the industry distribution chart, Karyopharm Therapeutics ranks #399 out of 636 companies in the Biotechnology industry, placing it in the top 62.7%.
Is Karyopharm Therapeutics' Days Inventory too high?
Karyopharm Therapeutics' current Days Inventory of 319.29 is 19% above median its 10-year median of 268.36. Over the past 10 years, this metric has ranged from a low of 52.47 to a high of 362.10. The Biotechnology industry median Days Inventory is 180.90. Karyopharm Therapeutics' value of 319.29 is 76.5% above this industry median. Based on the distribution chart, Karyopharm Therapeutics ranks #399 out of 636 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Karyopharm Therapeutics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Days Inventory compare to TNYA and HUMA?
According to the Biotechnology industry distribution chart, Karyopharm Therapeutics ranks #399 out of 636 companies for Days Inventory. This places Karyopharm Therapeutics in the lower half of its industry. The industry median Days Inventory is 180.90. Karyopharm Therapeutics' value of 319.29 is 76.5% above this benchmark. Historically, Karyopharm Therapeutics' own Days Inventory has ranged from 52.47 to 362.10 over the past decade. While the company's 10-year median is 268.36 vs. the industry median of 180.90, Karyopharm Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 180.90, based on 636 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Karyopharm Therapeutics's current Days Inventory of 319.29 is 76.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Karyopharm Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 180.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Karyopharm Therapeutics's current Days Inventory is 319.29, which is 19% above median its own 10-year median of 268.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Possible Value Trap. The stock's GF Value™ is $4.92, compared to a current price of $2.00 — trading 59.3% below its estimated fair value. The current Days Inventory is 319.29, which is 19% above median its 10-year median of 268.36 and 76.5% above the Biotechnology industry median of 180.90. Karyopharm Therapeutics' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Days Inventory is 319.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?
Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be undervalued.
The current stock price of $2.00 is trading 59.3% below its estimated GF Value™ of $4.92.
GuruFocus considers Karyopharm Therapeutics to be Possible Value Trap.
Key valuation signals for KPTI:
Days Inventory: 319.29 (19% above median its 10-year median of 268.36)
GF Value™: $4.92 vs. price of $2.00 (59.3% below fair value)
Industry Position: 76.5% above the Biotechnology median (#399 of 636)
No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
49GF Score
Get the complete analysis for KPTI
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KPTI has been successfully added to your 
